$8.07
-0.055[-0.68%]
At close: May 21
$8.07
0[0.00%]
PreMarket: 7:00AM EDT
Mind Medicine
(NASDAQ:MNMD)Latest News for Mind Medicine Stock (NASDAQ:MNMD)
Mind Medicine Stock (NASDAQ: MNMD)
Categories: All
Saturday, May 18, 2024
Wednesday, May 15, 2024
Monday, May 13, 2024
Friday, May 10, 2024
Thursday, May 09, 2024
Wednesday, May 08, 2024
Tuesday, May 07, 2024
Monday, May 06, 2024
Friday, April 19, 2024
Wednesday, April 17, 2024
Monday, April 15, 2024
Wednesday, April 10, 2024
Thursday, April 04, 2024
Monday, April 01, 2024
Friday, March 29, 2024
Wednesday, March 27, 2024
Wednesday, March 20, 2024
Thursday, March 14, 2024
- Reported Earlier, 'Indiana Lawmakers Send Psilocybin Research Funding Bill To Governor' - Marijuana MomentBenzinga Newsdesk - Mar 14, 2024, 12:42PM
- Why Robinhood Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving PremarketAvi Kapoor - Mar 14, 2024, 8:05AM
- HC Wainwright & Co. Reiterates Buy on Mind Medicine, Maintains $75 Price TargetBenzinga Newsdesk - Mar 14, 2024, 7:18AM
Wednesday, March 13, 2024
- Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionAvi Kapoor - Mar 13, 2024, 1:18PM
- FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private PlacementLara Goldstein - Mar 13, 2024, 11:33AM
Friday, March 08, 2024
Thursday, March 07, 2024
- S&P 500 Gains 1%; Kroger Earnings Top ViewsAvi Kapoor - Mar 7, 2024, 2:31PM
- Why HighPeak Energy Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionAvi Kapoor - Mar 7, 2024, 1:35PM
- MindMed Receives FDA 'Breakthrough Therapy' Designation For LSD As Anxiety Treatment, Shares Positive Results About Related Clinical TrialsLara Goldstein - Mar 7, 2024, 1:35PM
- Roth MKM Maintains Buy on Mind Medicine, Raises Price Target to $36Benzinga Newsdesk - Mar 7, 2024, 11:35AM
- What's Going On With MindMed Stock Thursday?Adam Eckert - Mar 7, 2024, 9:54AM
- MindMed shares are trading higher after the company received FDA Breakthrough Therapy Designation for its MM120 program in generalized anxiety disorder. The company also announced 12-week durability data from its Phase 2B study of MM120.Benzinga Newsdesk - Mar 7, 2024, 9:52AM
- Mind Medicine (MindMed) Priced Underwritten Offering of $175M Common Shares and Concurrent Private Placement at $6/ShareBenzinga Newsdesk - Mar 7, 2024, 7:17AM
- Mind Medicine Says FDA Has Granted Breakthrough Designation To Its MM120 (Lysergide D-tartrate) Program For Treatment Of Generalized Anxiety DisorderBenzinga Newsdesk - Mar 7, 2024, 6:02AM
Monday, March 04, 2024
Friday, March 01, 2024
Thursday, February 29, 2024
Wednesday, February 28, 2024
- MindMed's 2023 Financial Results And Business Recap: Milestones Amid Rising ExpensesLara Goldstein - Feb 28, 2024, 2:52PM
- MindMed 2023 EPS $(2.33), Cash Balance $99.7M As Of Dec. 31Benzinga Newsdesk - Feb 28, 2024, 7:07AM
- Earnings Scheduled For February 28, 2024Benzinga Insights - Feb 28, 2024, 6:24AM